A Thyroid Hormone Analog to Fight Heart Failure: Phase II Trial (DITPA)
NCT ID: NCT00032643
Last Updated: 2013-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
150 participants
INTERVENTIONAL
2004-06-30
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of the proposed Phase II study is to show safety and demonstrate a medication of efficacy of DITPA needed in patients with CHF. This study is a prerequisite for a larger Phase III trial which would determine whether mortality is improved with DITPA. To better define the appropriate doses, prior to the Phase II study we will conduct an initial pharmacokinetic study.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary hypothesis: DITPA will improve cardiovascular function and clinical status in patients with moderately severe heart failure and be similar to placebo on safety measures.
Secondary hypothesis:
Primary Outcomes: 1. Composite endpoint composed of cardiovascular mortality/morbidity, change in NYHA class and change in global assessment, and 2. safety.
Study Abstract: Congestive heart failure (CHF) affects 4-5 million Americans, and its prevalence is predicted to increase over the next few decades. Thyroid hormone has unique actions which make it a novel and potentially useful agent for treatment of CHF. Due to possible adverse effects of thyroid hormone, there is interest in developing analogs with fewer undesirable side effects. DITPA has been shown to improve diastolic function in both animal models and a recently completed double-blind placebo controlled trial in 19 humans.
The goal of the proposed Phase II study is to define the dose of DITPA needed to achieve hemodynamic improvement in patients with CHF. This study is a prerequisite for a larger Phase III trial which would determine whether mortality is improved with DITPA. To better define the appropriate doses, prior to the Phase II study we will conduct an initial pharmacokinetic study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
DITPA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DITPA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
To be enrolled, patients must:
1. be veterans,
2. have moderately severe CHF (NYHA class II, III or IV),
3. be 18 or older,
4. not have clinically important renal, hepatic or hematological disorders or clinically significant abnormal laboratory findings,
5. not have a pre-existing thyroid disease,
6. not have anemia (hematocrit less than 30%),
7. not have chronic pulmonary disease that limits exercise tolerance or requires use of chronic bronchodilator therapy or steroids,
8. be able to walk on the level for 6 minutes,
9. not have hemodynamically significant pericardial disease,
10. not have angina pectoris severe enough to require frequent administration of sublingual nitroglycerin,
11. not have acute myocardial infarction within 6 months of screening,
12. not have inoperable aortic stenosis,
13. not have symptomatic ventricular arrhythmias or ventricular arrhythmia requiring pharmacological therapy,
14. not have implanted cardioverter defibrillator,
15. not be taking amiodarone,
16. not have demonstrated non-compliance with prior medical regimes;
17. not be on an investigational drug,
18. not have a medical condition that, in the investigator's opinion, would make the patient ineligible,
19. not have an allergy to iodine or shellfish,
20. not be in sinus rhythm,
21. not be of childbearing potential,
22. have an ejection fraction greater than 40%.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
US Department of Veterans Affairs
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven Goldman, MD
Role: STUDY_CHAIR
Southern Arizona VA Health Care System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Southern Arizona VA Health Care System
Tucson, Arizona, United States
VA Greater Los Angeles Healthcare System, West LA
West Los Angeles, California, United States
VA Eastern Colorado Health Care System, Denver
Denver, Colorado, United States
VA Medical Center, Minneapolis
Minneapolis, Minnesota, United States
VA Medical Center, Cleveland
Cleveland, Ohio, United States
Ralph H Johnson VA Medical Center, Charleston
Charleston, South Carolina, United States
VA South Texas Health Care System, San Antonio
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
526
Identifier Type: -
Identifier Source: org_study_id